Kiniksa Pharmaceuticals Reports Strong 2025 ARCALYST Revenue and Positive 2026 Guidance
KNSA has more than doubled off its 52-week low of $17.82 on elevated volume (1.9× avg).
Summary
Kiniksa Pharmaceuticals reported strong unaudited 2025 ARCALYST revenue with 62% year-over-year growth and issued positive 2026 revenue guidance. The company also highlighted a robust cash position and pipeline advancements.
Key Events · Earnings and Guidance · KNSA
-
Strong 2025 ARCALYST Revenue
Unaudited net product revenue for ARCALYST reached $677.5 million for the full year 2025, representing approximately 62% year-over-year growth.
-
Positive 2026 Revenue Guidance
Kiniksa expects ARCALYST net product revenue for 2026 to be between $900 million and $920 million.
-
Robust Financial Position
As of December 31, 2025, the company had $414.1 million in cash, cash equivalents, and short-term investments with no debt, and expects to remain cash flow positive annually.
-
Pipeline Advancement
Phase 2 data for KPL-387 in recurrent pericarditis is expected in the second half of 2026, and a Phase 1 trial for KPL-1161 is planned to initiate by year-end 2026.
Analysis · KNSA · Life Sciences
Kiniksa Pharmaceuticals announced robust unaudited full-year 2025 net product revenue for ARCALYST, demonstrating significant year-over-year growth. The company also provided strong revenue guidance for 2026, indicating continued commercial momentum for its key product. Furthermore, Kiniksa reported a healthy cash position with no debt and expects to remain cash flow positive, providing financial stability to advance its pipeline. These updates, combined with progress on its KPL-387 and KPL-1161 programs, suggest a positive outlook for the company's financial performance and future growth catalysts.
How filings like this one have moved
In the 30 days to Sep 22, 2026, 34.8% of the 1044 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KNSA was trading at $41.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $17.82 to $44.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.